why choose us

First received: December 10, 2022

Clinical Trial: Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration

Study Status: Completed

Recruit Status: RECRUITING

Condition: Age-Related Macular Degeneration

Study Type: INTERVENTIONAL


Official Title: A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration

Brief Summary: VAN-2201 is Phase I clinical trial to assess the safety and tolerability of KH631 in subjects with neovascular AMD.KH631 is gene therapy designed to deliver a protein which targets and blocks VEGF via an adeno-associated viral vector.The standard of care for patients with neovascular AMD are anti-VEGF treaments, which have demonstrated improvement in vision and reduction in fluid.A one time placement of a product which inhibits VEGF has the potential to reduce the patient burden of regular intraocular injections.

Read more